These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1970095)
1. Randomisation and baseline characteristics in clinical trials. Moscucci M Lancet; 1990 Apr; 335(8696):1040-1. PubMed ID: 1970095 [No Abstract] [Full Text] [Related]
2. Randomisation and baseline comparisons in clinical trials. Altman DG; Doré CJ Lancet; 1990 Jan; 335(8682):149-53. PubMed ID: 1967441 [TBL] [Abstract][Full Text] [Related]
3. Randomisation in clinical trials. Beller EM; Gebski V; Keech AC Med J Aust; 2002 Nov; 177(10):565-7. PubMed ID: 12429008 [No Abstract] [Full Text] [Related]
4. The blind leading the blind: use and misuse of blinding in randomized controlled trials. Miller LE; Stewart ME Contemp Clin Trials; 2011 Mar; 32(2):240-3. PubMed ID: 21070890 [TBL] [Abstract][Full Text] [Related]
5. How well does blinding work in randomized controlled trials?: a counterpoint. Boehmer J; Yong P Clin Pharmacol Ther; 2009 May; 85(5):463-5. PubMed ID: 19381149 [No Abstract] [Full Text] [Related]
6. Blinding during data analysis and writing of manuscripts. Gøtzsche PC Control Clin Trials; 1996 Aug; 17(4):285-90; discussion 290-3. PubMed ID: 8889343 [No Abstract] [Full Text] [Related]
7. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Haahr MT; Hróbjartsson A Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210 [TBL] [Abstract][Full Text] [Related]
8. Blinding: an essential component in decreasing risk of bias in experimental designs. Forbes D Evid Based Nurs; 2013 Jul; 16(3):70-1. PubMed ID: 23696228 [No Abstract] [Full Text] [Related]
10. A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials. Mathieu E; Herbert RD; McGeechan K; Herbert JJ; Barratt AL J Clin Epidemiol; 2014 Jun; 67(6):667-71. PubMed ID: 24767518 [TBL] [Abstract][Full Text] [Related]
11. Blinding in pharmaceutical clinical trials: An overview of points to consider. Crisp A Contemp Clin Trials; 2015 Jul; 43():155-63. PubMed ID: 26044462 [TBL] [Abstract][Full Text] [Related]
13. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. Järvinen TL; Sihvonen R; Bhandari M; Sprague S; Malmivaara A; Paavola M; Schünemann HJ; Guyatt GH J Clin Epidemiol; 2014 Jul; 67(7):769-72. PubMed ID: 24560088 [TBL] [Abstract][Full Text] [Related]
14. A critique of the double-blind clinical trial. Part 1. Kiene H Altern Ther Health Med; 1996 Jan; 2(1):74-80. PubMed ID: 8795875 [TBL] [Abstract][Full Text] [Related]
15. Influence of blinding on treatment effect size estimate in randomized controlled trials of oral health interventions. Saltaji H; Armijo-Olivo S; Cummings GG; Amin M; da Costa BR; Flores-Mir C BMC Med Res Methodol; 2018 May; 18(1):42. PubMed ID: 29776394 [TBL] [Abstract][Full Text] [Related]
16. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
17. Double blind, you are the weakest link--good-bye! Devereaux PJ; Bhandari M; Montori VM; Manns BJ; Ghali WA; Guyatt GH ACP J Club; 2002; 136(1):A11. PubMed ID: 11829579 [No Abstract] [Full Text] [Related]
18. Clinical trials in nonulcer dyspepsia (NUD): a cautionary note. A closer look at "a double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia". Champion MC Can J Gastroenterol; 1997 Mar; 11(2):125-6. PubMed ID: 9113811 [No Abstract] [Full Text] [Related]